NWBO - Northwest Biotherapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2711
-0.0039 (-1.4182%)
At close: 3:55PM EST
Stock chart is not supported by your current browser
Previous Close0.2750
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume1,953,362
Market Cap87.117M
Beta1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.3940
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • NW Bio Announces Completion of $12 Million Financing
    PR Newswire9 days ago

    NW Bio Announces Completion of $12 Million Financing

    BETHESDA, Md., Dec. 4, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations.  The majority of the financing is being provided by new investors. The financing is in the form of Series A Convertible Preferred Stock and Warrants.  The Preferred Stock will be convertible into common stock, but only when common stock is available or after 6 months following issuance.  The Warrants will be exercisable for common stock, but only when common stock is available.  The shares are registered, but are subject to restrictions under which they may not be conveyed or traded until a shareholder vote takes place, pursuant to which the number of authorized shares is increased.  The shares are also subject to a voting agreement, under which the investors have agreed to vote in support of such increase in authorized shares.

  • Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube14 days ago

    Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Amgen Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., CytRx Corporation, ImmunoCellular Therapeutics, Ltd., Progenics Pharmaceuticals, Inc. and Bristol-Myers Squibb ... Read more (Read more...)

  • NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
    PR Newswirelast month

    NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

    BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed.  On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired.  This action is over.

  • NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
    PR Newswire2 months ago

    NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

    BETHESDA, Md., Oct. 25, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed.  On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired.  This action is over.

  • NW BIO Announces Registered Direct Offering Of $1.75 Million
    PR Newswire3 months ago

    NW BIO Announces Registered Direct Offering Of $1.75 Million

    BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20 per share.  Additionally, the investors will receive five year warrants to purchase up to approximately 4.375 million shares of common stock with an exercise price of $0.22 per share.

  • Capital Cube3 months ago

    ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
    PR Newswire3 months ago

    DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

    DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates; Overview Of A Broader Range Of DC Vax Public Data BETHESDA, Md. , Sept. 1, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW ...

  • Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube4 months ago

    Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., Amgen Inc., Progenics Pharmaceuticals, Inc., Merck & Co., Inc. and ImmunoCellular Therapeutics, Ltd. ... Read more (Read more...)

  • NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    PR Newswire6 months ago

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds

    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondholders entered into in March. The convertible debt issued in the transaction has a 3-year maturity.

  • Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today
    PR Newswire6 months ago

    Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today

    BETHESDA, Md., June 5, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that this afternoon at 3:00 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio, will deliver a webcast update on the Company's clinical trial programs. Dr. Bosch's presentation will include updates on the Company's Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM) brain cancer, as well as the Information Arm related to the GBM trial, and the Company's Phase I/II Trial of DCVax-Direct for inoperable solid tumors.

  • Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube7 months ago

    Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Northwest Biotherapeutics, Inc. – Celldex Therapeutics, Inc., Argos Therapeutics, Inc., Stemline Therapeutics, Inc., Agenus Inc., Amgen Inc., Progenics Pharmaceuticals, Inc., Merck & Co., Inc. and ImmunoCellular Therapeutics, Ltd. ... Read more (Read more...)

  • Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 20, 2017
    Capital Cube8 months ago

    Northwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Northwest Biotherapeutics, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 0.07 million, Net Earnings of USD -30.71 million. Change in operating cash flow of 36.29% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • TheStreet.com8 months ago

    Northwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K

    Imagine a derailed freight train carrying dumpsters on fire. That's an accurate description of the Northwest Bio 10-K filed Monday night.

  • TheStreet.com8 months ago

    Northwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse

    Northwest's inability to resolve the problems that froze the DCVax-L clinical trial -- and management's refusal to offer a public explanation for why it happened -- triggered the company's collapse.

  • Investopedia8 months ago

    Novocure Glioblastoma Drug Offers Survival Benefits

    Novocure said the combo of its brain cancer drug Optune with chemo significantly increased survival.

  • Investopedia9 months ago

    FDA Allows Ziopharm's Brain Cancer Drug Trial

    Ziopharm’s brain cancer drug, Ad-RTS-hIL-12, secured approval from the FDA to proceed in a clinical trial.

  • NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors
    PR Newswire9 months ago

    NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors

    BETHESDA, Md., March 23, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017. The Company sold to several institutional investors securities totaling 28,843,692 shares, comprised of 18,843,692 common shares at $.26 per share, and 10,000,000 shares of Class C Warrants pre-funded at the closing at $.25 cents per future exercisable shares, with a one cent per share additional payment to be made at the time of actual exercise of these warrants.  This arrangement is to enable investors to avoid exceeding 4.99% ownership while still funding $7.5 million.

  • NW BIO Announces Registered Direct Offering Of $7.5 Million
    PR Newswire9 months ago

    NW BIO Announces Registered Direct Offering Of $7.5 Million

    BETHESDA, Md., March 17, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $7.5 million.

  • TheStreet.com9 months ago

    Northwest Biotherapeutics agrees to pay bondholders $11 million, needs cash

    Northwest Biotherapeutics, a regular visitor to the capital markets, has negotiated a note payment schedule with Whitebox Advisors.

  • PR Newswire9 months ago

    NW Bio Reaches Agreement With Convertible Note Holders

    BETHESDA, Md., March 10, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors ("Whitebox"), holder of $11 million of NW Bio convertible senior notes. With these Notes otherwise due today, as previously disclosed, NW Bio and Whitebox have negotiated a time payment approach tailored to the Company's development schedule with increasing periodic payments over the course of the next 4 months.  As part of the consideration for these adjustments, Whitebox also will be receiving NW Bio common stock.

  • Investopedia10 months ago

    FDA Lifts Hold on Northwest Bio Cancer Drug Trial

    The FDA lifted an 18-month ban on Northwest Bio's cancer vaccine study.

  • PR Newswire10 months ago

    NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached

    BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Company's Phase III trial of DCVax®-L for Glioblastoma multiforme ("GBM") brain cancer (the "Trial").  The Company announced that the partial clinical hold on the Trial has been lifted by the FDA, and that the Trial has accumulated a sufficient number of events toward the progression-free survival ("PFS") endpoint, but not yet for the overall survival ("OS") endpoint. The Company remains blinded to all Trial data, and is only receiving and reporting updates on a blinded basis.